Home Clinical Topics Cardio-Pulmonary FDA approves new hemophilia treatment

FDA approves new hemophilia treatment

On June 6, the U.S. Food and Drug Administration (FDA) approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here